Clinical trials: Wilms' Tumor
Colorectal Cancer
WT1 in Colorectal Adenocarcinoma
Colorectal carcinoma is a major bublic health problem. It is due to several genetic mutations. Wilms' tumor1 (WT1) gene is a tumor suppressor gene that has been mutated in several human tumors.
- Trial name
- NCT07778628
- Testing
- immunohistochemical staining with WT1 antibody
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sohag University
Neuroblastoma, Nephroblastoma
Psychosocial Situation of Children With Rare Solid Abdominal Tumors and Their Families
Families of children with rare diseases (i.e., not more than 5 out of 10.000 people are affected) are often highly burdened with fears, insecurities and concerns regarding the affected child and his/her siblings.
- Conditions
- Neuroblastoma, Nephroblastoma, Hepatoblastoma
- Trial name
- PsyRareCare (NCT05245123)
- Where
- 2 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back…
- Conditions
- Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor
- Trial name
- NCT04322318
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Scan
- Where
- 205 sites in United States, Australia and 4 more
- Volunteers
- 256 people
- Sponsor
- Children's Oncology Group
Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Stage I Wilms Tumor
Gene Expression Profiles to Categorize Wilms Tumors
This laboratory study is using gene expression profiling to identify different categories of Wilms tumors. Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers…
- Conditions
- Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Stage I Wilms Tumor, Stage II Wilms Tumor, Stage III Wilms Tumor
- Trial name
- NCT00897637
- Testing
- laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- Children's Oncology Group
Neuroblastoma, Sarcoma
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon…
- Trial name
- NCT05135975
- Testing
- Cabozantinib
- Where
- 6 sites in United States
- Volunteers
- 86 people
- Sponsor
- Nationwide Children's Hospital
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Acute Myelogenous Leukemia, Myeloid Leukemia in Remission
Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia
The purpose of this study is to evaluate the safety and the efficacy of combined treatment strategy of WT1ASCI, infusion of ex vivo regulatory T cells depleted T lymphocytes and in vivo regulatory T cells depletion as…
- Conditions
- Acute Myelogenous Leukemia, Myeloid Leukemia in Remission, Effects of Immunotherapy
- Trial name
- ASCI (NCT01513109)
- Testing
- Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Jules Bordet Institute
Myelodysplastic Syndrome (MDS)
Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome
This study will test whether certain patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) or chronic myeloid leukemia (CML) can safely be vaccinated with two peptide vaccines derived from proteins called…
- Trial name
- NCT00270452
- Testing
- WT1 and PR1 Peptide Vaccine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Leukaemia, Myelocytic, Acute
Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)
This study is being done to evaluate the safety of a WT1 Antigen-Specific Cancer Immunotherapeutic (WT1 ASCI) as post-consolidation therapy in adult patients with WT1-positive Acute Myeloid Leukemia in first complete remission.
- Trial name
- NCT00725283
- Testing
- GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)
- Where
- 10 sites in United States, France
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Kidney Cancer
Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells.
- Trial name
- NCT00002611
- Testing
- dactinomycin, filgrastim, cyclophosphamide
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 3,031 people
- Sponsor
- Children's Oncology Group
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Low Grade Glioma
- Trial name
- NCT03233204
- Testing
- Olaparib
- Where
- 113 sites in United States, Puerto Rico
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Adult Cystic Nephroma, Anaplastic Kidney Wilms Tumor
Study of Kidney Tumors in Younger Patients
This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that…
- Conditions
- Adult Cystic Nephroma, Anaplastic Kidney Wilms Tumor, Angiolipoma, Cellular Congenital Mesoblastic Nephroma
- Trial name
- NCT00898365
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Where
- 248 sites in United States, Australia and 5 more
- Volunteers
- 8,000 people
- Sponsor
- Children's Oncology Group
Wilm's Tumor
National Wilm's Tumor Study Late Effects
The Late Effects Study is being conducted in order to answer scientific questions and to serve as a resource for Wilms tumor patients and their families.
- Trial name
- NCT00228696
- Testing
- none, screening only
- Where
- United States
- Sponsor
- Emory University
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a…
- Conditions
- Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma
- Trial name
- NCT04284774
- Testing
- Tipifarnib
- Where
- 172 sites in United States, Puerto Rico
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Pediatric Renal Tumor, Metastatic Osteosarcoma
Indo-cyanine Green (ICG) in Paediatric Oncology MIS
Indo-cyanine green (ICG) is a dye that has been used for a variety of adult and paediatric uses since 1956. Over the past few years, near infrared (NIRF) technology has been developed which allow is use as a fluorescence agent…
- Conditions
- Pediatric Renal Tumor, Metastatic Osteosarcoma, Metastatic Ewing Sarcoma, Pulmonary Metastasis
- Trial name
- NCT04854018
- Testing
- Indocyanine green
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Birmingham Women's and Children's NHS Foundation Trust
Neuroblastoma, Rhabdomyosarcoma
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
This is a Phase I, open-label, dose-escalation trial of JX-594 (Pexa-Vec) in pediatric patients with advanced/metastatic, unresectable solid tumors refractory to standard therapy and/or the patient does not tolerate standard…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Wilm's Tumor
- Trial name
- NCT01169584
- Testing
- Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Jennerex Biotherapeutics
Leukaemia (Acute), Leukaemia (Chronic)
WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation
The study is not currently recruiting new subjects due to an interruption in funding from its sponsors. Efforts are under way to re-establish funding, however, the study is currently on-hold pending the outcome of these…
- Conditions
- Leukaemia (Acute), Leukaemia (Chronic), Leukaemia (Acute Myeloid), Leukaemia (Acute Lymphoblastic)
- Trial name
- WIN (NCT01334060)
- Testing
- p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine
- Where
- 3 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Lymphoma, Brain Neoplasms
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Background: The anti-cancer drug RO4929097 is being tested for its ability to block blood vessel growth to tumors and slow or stop the growth of cancer cells.
- Conditions
- Lymphoma, Brain Neoplasms, Sarcoma, Osteosarcoma
- Trial name
- NCT01236586
- Testing
- RO4929097, Dexamethasone
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Ewing's Sarcoma, Soft Tissue Sarcoma
Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors
This study uses a double autologous peripheral blood stem cell rescue (PBSC) following dose-intensive chemotherapy for the treatment of high-risk pediatric solid tumors.
- Conditions
- Ewing's Sarcoma, Soft Tissue Sarcoma, Hepatoblastoma, Hodgkin's Disease
- Trial name
- NCT00179816
- Testing
- High-Dose Chemotherapy with Tandem PBSC Rescue.
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Solid Tumor (Excluding CNS), Liver Cell Carcinoma
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
This Phase 1, open-label, non-randomized study will enroll pediatric and young adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors expressing glypican-3 (GPC3) to examine the safety…
- Conditions
- Solid Tumor (Excluding CNS), Liver Cell Carcinoma, Malignant Rhabdoid Tumor, Yolk Sac Tumor
- Trial name
- IMPACT (NCT07148050)
- Testing
- SC-CAR.GPC3xIL15.21 CAR T cells
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Seattle Children's Hospital